1. Scrip
  2. >>Focus On Asia
  3. >>China

Abogen and Neurophth Lead China mRNA, Gene And Cell Therapy Funding Rush

 
• By Dexter Jie Yan

Total of $571m raised in China from 10 venture capital and private equity funding deals betting heavily on mRNA and targeted oncology, as well as gene and cell therapies.

fund raising
Chinese biotechs continued to attract mega-funds in the last two weeks of November • Source: Alamy

Since LianBio's initial public listing on Nasdaq in the US, Chinese biotechs continued to attract substantial funding in the last two weeks of November, with mRNA technologies bagging the most attention.

On 29 November, ABOGEN INC announced the completion of a $300m series C+ round on top of the Chinese messenger RNA

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.